Trial Profile
A prospective, multi-centre, double-blind, randomized, study to evaluate the safety and efficacy of Saroglitazar 4mg versus Placebo in the treatment of HIV associated lipodystrophy. - PRESS IX
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2019
Price :
$35
*
At a glance
- Drugs Saroglitazar (Primary)
- Indications HIV-associated lipodystrophy syndrome
- Focus Therapeutic Use
- Sponsors Zydus Lifesciences
- 27 Sep 2016 New trial record